Effects of glycemic control and other determinants on vascular disease in type 2 diabetes

American Journal of Medicine

Volumn 113, Issue 6 SUPPL., 2002, Pages 12-22

  Sobel, Burton E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; BLOOD VESSEL WALL; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONFERENCE PAPER; DISEASE PREDISPOSITION; ENERGY METABOLISM; FIBRINOLYSIS; HEART MUSCLE ISCHEMIA; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE FUNCTION; UNSTABLE ANGINA PECTORIS;

EID: 0037191116     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(02)01277-9     Document Type: Conference Paper

References (68)

1. American Diabetes Association. Diabetes Facts and Figures: The Dangerous Toll of Diabetes. Available at: www.diabetes.org/ada/facts.asp. Accessed June 12, 2001.
2. Geiss L.S., Herman W.H., Smith P.J. Mortality in non-insulin-dependent diabetes. National Diabetes Data Group Diabetes in America. 2nd ed:1995;233-252 National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, MD.
3. Haffner S.M., Lehto S., Rönnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 339:1998;229-234.
4. Pyörälä K., Laakso M., Uusitupa M. Diabetes and atherosclerosis an epidemiological view . Diabetes Metab Rev. 3:1997;463-524.
5. Kuusisto J., Mykkänen L., Pyörälä K., Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 43:1994;960-967.
6. Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329:1993;977-986.
7. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
8. Stratton I.M., Adler A.I., Neil H.A.W., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) prospective observational study . BMJ. 321:2000;405-412.
9. DIGAMI (Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group, Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ. 314:1997;1512-1515.
10. Bierman E.L. Atherogenesis in diabetes. Arterioscler Thromb. 12:1992;647-656.
11. Calles-Escandon J., Mirza S.A., Sobel B.E., Schneider D.J. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes. 47:1998;290-293.
12. Hamsten A., Wiman B., De Faire U., Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 313:1985;1557-1563.
13. Jones R.L. Fibrinopeptide-A in diabetes mellitus relation to levels of blood glucose, fibrinogen disappearance, and hemodynamic changes . Diabetes. 34:1985;836-843.
14. Keber I., Keber D. Increased plasminogen activator inhibitor activity in survivors of myocardial infarction is associated with metabolic risk factors of atherosclerosis. Haemostasis. 22:1992;187-194.
15. Lupu C., Calb M., Ionescu M., Lupu F. Enhanced prothrombin and intrinsic factor X activation on blood platelets from diabetic patients. Thromb Haemost. 70:1993;579-583.
16. Mansfield M.W., Heywood D.M., Grant P.J. Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. Circulation. 94:1996;2171-2176.
17. McGill J.B., Schneider D.J., Arfken C.L., et al. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 43:1994;104-109.
18. Prescott S.M., McIntyre T.M., Zimmerman G.A. Events at the vascular wall the molecular basis of inflammation . J Invest Med. 49:(suppl):2001;104-111.
19. Reaven G.M. Syndrome X 6 years later . J Intern Med. 736:(suppl):1994;13-22.
20. Collen D. Thrombolytic therapy. Thromb Haemost. 78:1997;742-746.
21. Juhan-Vague I., Alessi M.C., Morange P.E. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med. 32:(suppl 1):2000;78-84.
22. Juhan-Vague I., Alessi M.C. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost. 78:1997;656-660.
23. Nordt T.K., Bode C., Sobel B.E. Stimulation in vivo of expression of intra-abdominal adipose tissue plasminogen activator inhibitor type-1 by proinsulin. Diabetologia. 44:2001;1121-1124.
24. Schneider D.J., Ricci M.A., Taatjes D.J., et al. Changes in arterial expression of fibrinolytic system proteins in atherogenesis. Arterioscler Thromb Vasc Biol. 17:1997;3294-3301.
25. Schneider D.J., Sobel B.E. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I implications for vascular disease in hyperinsulinemic states . Proc Natl Acad Sci USA. 88:1991;9959-9963.
26. Nordt T.K., Sawa H., Fujii S., et al. Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo. J Mol Cell Cardiol. 30:1998;1535-1543.
27. Nordt T.K., Sawa H., Fujii S., Sobel B.E. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation. 91:1995;764-770.
28. Nordt T.K., Schneider D.J., Sobel B.E. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin a potential risk factor for vascular disease . Circulation. 89:1994;321-330.
29. Nordt TK, Lutzi S, Ruef J, et al. Attenuation by fibrates of expression of plasminogen activator inhibitor type-1 expression in cultured human arterial smooth muscle cells. Thromb Haemost. 2001;86:1305-1313.
30. Fattal P.G., Schneider D.J., Sobel B.E., Billadello J.J. Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J Biol Chem. 267:1992;12412-12415.
31. Bypass Angioplasty Revascularization Investigation (BARI) Investigators . Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 335:1996;217-225.
32. BARI Investigators . Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease the Bypass Angioplasty Revascularization Investigation (BARI) . Circulation. 96:1997;1761-1769.
33. Sobel B.E. Potentiation of vasculopathy by insulin implications from an NHLBI clinical alert . Circulation. 93:1996;1613-1615.
34. Sobel B.E., Woodcock-Mitchell J., Schneider D.J., et al. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients. Circulation. 97:1998;2213-2221.
35. Pandolfi A., Cetrullo D., Polishuck R., et al. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol. 21:2001;1378-1382.
36. Clowes A.W., Clowes M.M., Au Y.P.T., et al. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res. 67:1990;61-67.
37. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 91:1995;2844-2850.
38. Gotsman M.S., Rozenman Y., Admon D., et al. Changing paradigms in thrombolysis in acute myocardial infarction. Int J Cardiol. 59:1997;227-242.
39. Carmeliet P., Moon L., Lijnen R., et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation. Circulation. 96:1997;3180-3191.
40. Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol. 63:1989;114E-120E.
41. Davies M.J., Woolf N., Rowles P.M., Pepper J. Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. Br Heart J. 60:1988;459-464.
42. Davies M.J. Stability and instability two faces of coronary atherosclerosis . Circulation. 94:1996;2013-2020.
43. Sobel BE. Cardiovascular disease in type 2 diabetes: implications of elevated PAI-1 in blood and tissues [National Diabetes Education Initiative Web site]. Available at: http://www.ndei.org/content/symposia/symposia_highlights/111300/ abstract02.asp . Accessed July 25, 2001/.
44. Ehrmann D.A., Schneider D.J., Sobel B.E., et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 82:1997;2108-2116.
45. Kruszynska Y.T., Yu J.G., Olefsky J.M., Sobel B.E. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes. 49:2000;633-639.
46. Nagi D.K., Yudkin J.S. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care. 16:1993;621-629.
47. Inzucchi S.E., Maggs D.G., Spollet G.R., et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 338:1998;867-872.
48. Velazquez E.M., Mendoa S.G., Wan P., Glueck C.J. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism. 46:1997;454-457.
49. Minamikawa J., Tanaka S., Yamauchi M., et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 83:1998;1818-1820.
50. Maroko P.R., Kjekshus J.K., Sobel B.E., et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation. 43:1971;67-82.
51. Haffner S.M. Coronary heart disease in patients with diabetes. N Engl J Med. 342:2000;1040-1042.
52. Sobel B.E. Acceleration of restenosis by diabetes pathogenetic implications . Circulation. 103:2001;1185-1187.
53. Chen Y., Billadello J.J., Schneider D.J. Identification and localization of a fatty acid response region in the human plasminogen activator inhibitor-1 gene. Arterioscler Thromb Vasc Biol. 20:2000;2696-2701.
54. 1 receptor in rat aortic and cardiac PAI-1 gene expression. Arterioscler Thromb Vasc Biol. 20:2000;2297-2302.
55. Feener E.P., Northrup J.M., Aiello L.P., King G.L. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest. 95:1995;1353-1362.
56. Hamdan A.D., Quist W.C., Gagne J.B., Feener E.P. Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation. 93:1996;1073-1078.
57. Ridker P.M., Vaughan D.E. Potential antithrombotic and fibrinolytic properties of the angiotensin converting enzyme inhibitors. J Thromb Thrombolysis. 1:2001;251-257.
58. Zaman A.K.M.T., Fujii S., Sawa H., et al. Angiotensin-converting enzyme inhibition attenuates hypofibrinolysis and reduces cardiac perivascular fibrosis in genetically obese diabetic mice. Circulation. 103:2001;3123-3128.
59. Kabbani S.S., Watkins M.W., Ashikaga T., et al. Platelet reactivity characterized prospectively a determinant of outcome 90 days after percutaneous coronary intervention . Circulation. 104:2001;181-186.
60. Van Belle E., Ketelers R., Bauters C., et al. Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up a key determinant of survival in diabetics after coronary balloon angioplasty . Circulation. 103:2001;1218-1224.
61. Bhatt D.L., Marso S.P., Lincoff M., et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 35:2000;922-928.
62. Théroux P., Alexander J. Jr, Pharand C., et al. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study . Circulation. 102:2000;2466-2472.
63. Stone P.H., Muller J.E., Hartwell T., et al. for the MILIS Study Group . The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis . J Am Coll Cardiol. 14:1989;49-57.
64. Malmberg K., Yusuf S., Gerstein H.C., et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry . Circulation. 102:2000;1014-1019.
65. Stanley W.C., Lopaschuk G.D., McCormack J.G. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res. 34:1997;25-33.
66. Rodrigues B., Cam M.C., McNeill J.H. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem. 180:1998;53-57.
67. Anderson J.R., Khou S., Nawarskas J.J. Ranolazine a potential new treatment for chronic stable angina. Heart Dis. 3:2001;263-269.
68. Brownlee M. Glycation and diabetic complications. Diabetes. 43:1994;836-841.